Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
AG Patel, SB De Lorenzo, KS Flatten, GG Poirier… - Clinical cancer …, 2012 - AACR
Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are undergoing extensive clinical
testing for their single-agent activity in homologous recombination (HR)-deficient tumors and …
testing for their single-agent activity in homologous recombination (HR)-deficient tumors and …
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status
CJ Huntoon, KS Flatten, AE Wahner Hendrickson… - Cancer research, 2013 - AACR
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway
that licenses repair and cell survival processes. In this study, we examined the respective …
that licenses repair and cell survival processes. In this study, we examined the respective …
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which
stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine …
stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine …
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival
LM Karnitz, KS Flatten, JM Wagner, D Loegering… - Molecular …, 2005 - ASPET
Two signaling pathways are activated by antineoplastic therapies that damage DNA and
stall replication. In one pathway, double-strand breaks activate ataxia-telangiectasia mutated …
stall replication. In one pathway, double-strand breaks activate ataxia-telangiectasia mutated …
Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis
RS Maskey, KS Flatten, CJ Sieben… - Nucleic acids …, 2017 - academic.oup.com
Germline mutations in SPRTN cause Ruijs–Aalfs syndrome (RJALS), a disorder characterized
by genome instability, progeria and early onset hepatocellular carcinoma. Spartan, the …
by genome instability, progeria and early onset hepatocellular carcinoma. Spartan, the …
[HTML][HTML] Enhanced killing of cancer cells by poly (ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes
AG Patel, KS Flatten, PA Schneider, NT Dai… - Journal of biological …, 2012 - ASBMB
Poly(ADP-ribose) polymerase-1 (PARP1) plays critical roles in the regulation of DNA repair.
Accordingly, small molecule inhibitors of PARP are being developed as agents that could …
Accordingly, small molecule inhibitors of PARP are being developed as agents that could …
[HTML][HTML] Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
…, S Verdura, A Arbusà, PA Schneider, KS Flatten… - Cell death & …, 2021 - nature.com
Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention
in the last decade as potential targeted cancer therapies. However, little is known about the …
in the last decade as potential targeted cancer therapies. However, little is known about the …
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
…, JC Shing, KL Peterson, KS Flatten… - Blood, The Journal …, 2012 - ashpublications.org
The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic
signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR …
signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR …
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
…, MJ Maurer, AL Oberg, XW Meng, KS Flatten… - Gynecologic …, 2019 - Elsevier
Objective Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in
homologous recombination- (HR-) deficient ovarian cancer and are undergoing testing in …
homologous recombination- (HR-) deficient ovarian cancer and are undergoing testing in …
[HTML][HTML] CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
…, ND Vincelette, BD Koh, RM Naylor, KS Flatten… - …, 2014 - ncbi.nlm.nih.gov
Novel combinations targeting new molecular vulnerabilities are needed to improve the outcome
of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel …
of patients with acute myeloid leukemia. We recently identified WEE1 kinase as a novel …